Urine matrix metalloproteinases and their extracellular inducer EMMPRIN in children with chronic kidney disease

References

• Eddy AA. Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int. 2014;4:2–8
   Web of Science ®Google Scholar
• Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis – Evidence for and against. Int J Exp Pathol. 2011;92:143–150
   PubMed Web of Science ®Google Scholar
• Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 2010;21:212–222
   PubMed Web of Science ®Google Scholar
• Loeffler I, Wolf G. Transforming growth factor-beta and the progression of renal disease. Nephrol Dial Transplant. 2014; 29(suppl 1):i37–i45
   PubMedGoogle Scholar
• Lopez-Hernandez FJ, Lopez-Novoa JM. Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012;347:141–154
   PubMed Web of Science ®Google Scholar
• Decleves AE, Sharma K. Novel targets of antifibrotic and anti-inflammatory treatment in CKD. Nat Rev Nephrol. 2014;10:257–267
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function and biochemistry. Circ Res. 2003;92:827–839
   PubMed Web of Science ®Google Scholar
• Iimura O, Takahashi H, Yashiro T, et al. Effect of ureteral obstruction on matrix metalloproteinase-2 in rat renal cortex. Clin Exp Nephrol. 2004;8:223–229
   PubMedGoogle Scholar
• Gonzalez-Avila G, Iturria C, Vadillo-Ortega F, Ovalle C, Montaño M. Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology. 1998;66:196–204
   PubMed Web of Science ®Google Scholar
• Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol. 2003;162:1937–1949
   PubMed Web of Science ®Google Scholar
• Tan TK, Zheng G, Hsu TT, et al. Macrophage matrix metalloproteinase-9 mediates epithelial–mesenchymal transition in vitro in murine renal tubular cells. Am J Pathol. 2010;176:1256–1270
   PubMed Web of Science ®Google Scholar
• Kato N, Kosugi T, Sato W, et al. Basigin/CD147 promotes renal fibrosis after unilateral ureteral obstruction. Am J Pathol. 2011;178:572–579
   PubMed Web of Science ®Google Scholar
• Pawlak K, Myśliwiec M, Pawlak D. Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis. Clin Biochem. 2011;44:838–843
   PubMed Web of Science ®Google Scholar
• Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. Clin Chim Acta. 2006;366:243–248
   PubMed Web of Science ®Google Scholar
• Musiał K, Zwolińska D. Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment. Cell Stress Chaperones. 2011;16:97–103
   PubMed Web of Science ®Google Scholar
• Musiał K, Zwolińska D. New markers of apoptosis in children on chronic dialysis. Apoptosis. 2013;18:77–84
   PubMed Web of Science ®Google Scholar
• He W, Tan RJ, Li Y, et al. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/b-catenin activity in CKD. J Am Soc Nephrol. 2012;23:294–304
   PubMed Web of Science ®Google Scholar
• Hirt-Minkowski P, Marti HP, Hönger G, et al. Correlation of serum and urinary matrix metalloproteinases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation. Transplant Immunol. 2014;30:1–6
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–637
   PubMed Web of Science ®Google Scholar
• Lurbe E, Cifkova R, Cruickshank JK, et al. Management of high blood pressure in children and adolescents: Recommendations of the European Society of Hypertension. J Hypertens. 2009;27:1719–1742
   PubMed Web of Science ®Google Scholar
• Tang Y, Kesavan P, Nakada MT, Yan L. Tumor-stroma interaction: Positive feedback regulation of extracellular matrix inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res. 2004;2:73–80
   PubMed Web of Science ®Google Scholar
• Di Carlo A. Matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in sera and urine of patients with renal carcinoma. Oncol Lett. 2014;7:621–626
   PubMed Web of Science ®Google Scholar
• Mohammed MA, Seleim MF, Abdalla MS, Sharada HM, Abdel Wahab AH. Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. BMC Urol. 2013;13:25
   PubMedGoogle Scholar
• Wilson CL and Matrisian LM. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol. 1996;28:123–136
   PubMed Web of Science ®Google Scholar
• Szarvas T, Singer BB, Becker M, et al. Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int. 2011;107:1069–1073
   PubMed Web of Science ®Google Scholar
• Bhagirath D, Abrol N, Khan R, Sharma M, Seth A, Sharma A. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder. Clin Chim Acta. 2012;413:1641–1646
   PubMed Web of Science ®Google Scholar